Affinity Wealth Management’s Theriva Biologics TOVX Stock Holding History

Affinity Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$30K	Buy	+4	New	+$23.1K	0.02%	71

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Affinity Wealth Management's TOVX Position: Q3 2017 in Review

Affinity Wealth Management opened a new position in Theriva Biologics (TOVX) in Q3 2017: 4 shares worth $30K. The stake represents 0.02% of the portfolio and ranks #71 among its holdings.

51 funds tracked by Wall St. Rank hold TOVX as of Q3 2017.

Affinity Wealth Management held 4 shares of Theriva Biologics worth $30K as of Q3 2017.
Theriva Biologics was a new Affinity Wealth Management position in Q3 2017.
Theriva Biologics made up 0.02% of Affinity Wealth Management's portfolio in Q3 2017, its #71 holding.
51 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2017.

Based on Affinity Wealth Management's 13F filing for Q3 2017, filed 14 Nov 2017.